Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0

作者：

Gaber, Tarek ^{[1
]}

Shippen, Clare ^{[2
]}

机构：

[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England

[2] North West Deanery, Rehabil Med, Manchester, Lancs, England

来源：

PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期

关键词：

D O I：

10.1002/pnp.486

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.

引用

页码：5 / 6

页数：2

共 50 条

[41] Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis
Sorensen, Per Soelberg
Centonze, Diego
Giovannoni, Gavin
Montalban, Xavier
Selchen, Daniel
Vermersch, Patrick
Wiendl, Heinz
Yamout, Bassem
Salloukh, Hashem
Rieckmann, Peter
NEUROLOGY, 2020, 94 (15)
[42] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Michels, Renee Else
de Fransesco, Maria
Mahajan, Koshu
Hengstman, Gerald J. D.
Schiffers, Krijn M. H.
Budhia, Sangeeta
Harty, Gerard
Krol, Marieke
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
[43] Reduced Grey Matter Atrophy in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
Battaglini, Marco
Sormani, Maria Pia
Luchetti, Ludovico
Gentile, Giordano
Cortese, Rosa
Alexandri, Nektaria
De Stefano, Nicola
NEUROLOGY, 2021, 96 (15)
[44] The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary
Vermersch, Patrick
Galazka, Andrew
Dangond, Fernando
Damian, Doris
Wong, Schiffon L.
Jack, Dominic
Harty, Gerard
NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (06) : 285 - 293
[45] NICE Technology Appraisal No 84
Ridley, S
ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2006, 41 (01): : 44 - 46
[46] Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
Lobo, C.
Lee, J.
Chin, A.
Lui, S.
Chen, X.
Evans, E.
Phillips, A. L.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 192 - 193
[47] A Multicenter Real-World Data of Cladribine Tablets in Patients with Multiple Sclerosis in Turkey
Koseoglu, Mesrure
Omerhoca, Sami
Balci, Fatma Belgin
Unal, Aysun
Ozdemir, Zeynep
Yuksel, Burcu
Celik, Rabia Gokcen Gozubatik
Toprak, Ufuk Emre
Gursoy, Esra Azize
Icen, Nilufer Kale
Altunrende, Burcu
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1017 - 1017
[48] HEALTH STATE UTILITIES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TREATED WITH CLADRIBINE TABLETS
Wong, S. L.
Hohnhorst, P., V
Hettle, R.
Konings, P.
VALUE IN HEALTH, 2017, 20 (09) : A725 - A725
[49] Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
Giovannoni, Gavin
Coyle, Patricia K.
Vermersch, Patrick
Walker, Bryan
Aldridge, Julie
Nolting, Axel
Galazka, Andrew
Lemieux, Caroline
Leist, Thomas P.
FRONTIERS IN IMMUNOLOGY, 2021, 12
[50] Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
Comi, Giancarlo
Cook, Stuart
Giovannoni, Gavin
Rieckmann, Peter
Sorensen, Per Soelberg
Vermersch, Patrick
Galazka, Andrew
Nolting, Axel
Hicking, Christine
Dangond, Fernando
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 168 - 174

← 1 2 3 4 5 →